Another nanobody-based tri-specific Tandem CAR (TanCAR) T-cell targeting CD33, CD123, and CLL1 were designed to address antigen-negative escape and intra-tumor heterogeneity in acute myeloid leukemia (AML). This evidence concerns the gene CD33 and neoplasm.